Nine in Ten? The Denominator Behind Novo’s Wegovy Liver Fat Data

Dr. Ethan Lazarus, MD, DABOM, DABFM, MFOMA | Clinical Nutrition Center | October 5, 2026

Novo Nordisk announced at EASD in Milan on October 1 that 23 of 26 participants with obesity and elevated liver fat reached normal liver fat levels after 72 weeks on Wegovy. That is the “nine in ten” figure.

Here is the denominator problem.

Those 26 people came from a 55-person imaging subgroup. That subgroup came from a pooled trial population of 1,919. The liver fat result — measured by MRI-PDFF, the gold-standard non-invasive method — was never a pre-specified endpoint. This was a post hoc, exploratory pooled analysis of STEP UP and STEP UP T2D. The parent trials were designed to measure weight loss.

Mean liver fat declined from 8.8% at baseline to 3.1% at week 72 across the 55-person imaging cohort. Novo calls that a reduction of nearly two-thirds. That number is real. The framing is the issue.

The 88.5% normalization rate applies only to the 26 participants who started above the 5% threshold. No placebo-comparison figure was provided. Without it, there is no way to know how much of that normalization reflects the drug versus weight loss alone or other factors.

Liver fat is a surrogate marker. Reduced liver fat is not the same as reduced fibrosis, reduced cirrhosis, or fewer liver-related deaths. The UK MHRA approved semaglutide for MASH in adults with moderate-to-advanced fibrosis on July 3, 2026. The US regulatory position is separate and I am not stating a specific FDA status here.

What is true: this is a real signal from peer-reviewed trials, analyzed after the fact. Nine in ten of the people who had imaging and started with elevated liver fat reached normal levels. The number behind the headline is 23 people.

For a Denver patient who has been told they have fatty liver: this data is relevant to the conversation. It does not replace it. When you see “nine in ten” in a headline, ask two questions. How many people is that? Was the outcome pre-specified, or did they look for it after the fact? Both things can be true at the same time — and knowing the difference is not splitting hairs. It is the difference between a headline and a clinical signal.

Frequently Asked Questions

How many people were actually in the Wegovy liver fat study?

The headline figure of 88.5% reflects 23 out of 26 participants. Those 26 came from a 55-person imaging subgroup, which came from a pooled trial population of 1,919 adults across the STEP UP and STEP UP T2D trials. Liver fat was measured directly in only the 55-person subgroup using MRI-PDFF.

What did the study actually find about liver fat?

Mean liver fat in the 55-person imaging cohort declined from 8.8% at baseline to 3.1% at week 72, which Novo Nordisk describes as a reduction of nearly two-thirds. Among the 26 participants who started above the 5% liver fat threshold, 88.5% reached below 5% by week 72.

Was this a planned result or found after the fact?

It was a post hoc, exploratory analysis. Liver fat was never a pre-specified primary or secondary endpoint of the STEP UP or STEP UP T2D trials. Those trials were designed to measure changes in body weight. The liver findings were examined after the fact. The parent trials are peer-reviewed, but this specific liver analysis has not been published separately for peer review.

Does less liver fat mean less liver damage?

Not necessarily. Liver fat is a surrogate marker, which means it stands in for an outcome researchers hope matters. Reduced liver fat is not the same as reduced fibrosis, reduced cirrhosis, or fewer liver-related deaths. Those are different endpoints requiring different and longer studies. No placebo-comparison figure was provided for the 88.5% normalization rate, so it is not possible to say how much of the change was attributable to the drug itself versus the weight loss.

Is Wegovy approved to treat fatty liver disease?

In the United Kingdom, the MHRA approved semaglutide for metabolic-associated steatohepatitis, or MASH, in adults with moderate-to-advanced liver fibrosis on July 3, 2026. Approval status differs by country and by indication, so check with your own clinician what applies to you. Fatty liver is also frequently found incidentally on imaging done for unrelated reasons, which is common in people with obesity.

Understanding Your Liver Health Numbers?

Patients who have been told they have fatty liver often benefit from a medical weight loss evaluation. Our physician-led team in Greenwood Village, CO can help you read the real data and find a plan that treats the whole picture — not just the headline.

Book a Consultation

CNC Greenwood Village clinic  ·  (303) 750-9454

author avatar
Dr. Lazarus Owner / Physician
Physician at Clinical Nutrition Center. Helping patients full-time with medical management of obesity and life-long weight control.
Share your love

Leave a Reply

Your email address will not be published. Required fields are marked *

Manage Cookies

Necessary
Required for site functions.
Analytics
Allows Google Analytics tracking.